Liver fibrosis, as one of the leading causes of liver-related morbidity and mortality, has no Food and Drug Administration (FDA)-approved antifibrotic
therapy yet. Although microRNA-29b (miRNA-29b) and microRNA-122 (miRNA-122) have great potential in treating
liver fibrosis via regulating profibrotic genes in hepatic stellate cells (HSCs), it is still a challenge to achieve a HSC-targeted and meanwhile noninvasively trackable delivery of
miRNAs in vivo. Herein, a pH-sensitive and
vitamin A (VA)-conjugated copolymer VA-
polyethylene glycol-
polyethyleneimine-poly(N-(N',N'-diisopropylaminoethyl)-co-benzylamino) aspartamide (T-PBP) is synthesized and assembled into superparamagnetic
iron oxide (
SPIO)-decorated cationic
micelle for
miRNA delivery. The T-PBP
micelle efficiently transports the miRNA-29b and miRNA-122 to HSC in a magnetic resonance imaging-visible manner, resulting in a synergistic antifibrosis effect via downregulating the expression of
fibrosis-related genes, including
collagen type I alpha 1, α-smooth muscle actin, and
tissue inhibitor of metalloproteinase 1. Consequently, the HSC-targeted combination
therapy with miRNA-29b and miRNA-122 demonstrates a prominent antifibrotic efficacy in terms of improving liver function and relieving hepatic
fibrosis.